Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

First-Generation TRK Inhibitors: Clinical Evidence and Indications

Source: The Expanding Clinical Application of TRK Inhibitors in Cancer Care: A Podcast Series
In this podcast episode, listen to an engaging discussion between George D. Demetri, MD, and Alexander Drilon, MD, on key clinical trials leading to FDA approvals of first-generation TRK inhibitors, where these agents fit into treatment paradigms for various solid tumors, and considerations for choosing among currently available TRK inhibitors.
George D. Demetri, MD
Alexander Drilon, MD
Released: October 15, 2021

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:

  • Basket trials leading to FDA approvals of larotrectinib and entrectinib
  • Current pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLC
  • Sequencing treatment with TRK inhibition in patients with solid tumors
  • Clinically relevant similarities and differences between larotrectinib and entrectinib

Information on this Educational Activity

Faculty

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received funds for research support and consulting fees from Bayer, Ignyta, Loxo, and Roche and serves as a member of the board of directors for Blueprint Medicines.
Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received honoraria or served on the advisory boards of 14ner/Elevation Oncology, AbbVie, ArcherDX, AstraZeneca, AXIS, BeiGene, BergenBio, Blueprint Medicines, Chugai Pharm, EMD Serono, EPG Health, Exelixis, Harborside, Helsinn, Hengrui, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Liberum, Melendi, Merus, Monopteros, MORE Health, Novartis, Nuvalent, Pfizer, Remedica, Repare RX, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; has received funding paid to his institution from Exelixis, GlaxoSmithKline, Pfizer, PharmaMar, Teva, and Taiho; has received funds for research support from Foundation Medicine; and has received other financial or material support from Boehringer Ingelheim, Merck, Merus, and Puma.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Stacey Stein, MD, on systemic therapy for advanced hepatocellular carcinoma, including most recent clinical data on first-line and second-line treatment options in this Clinical Care Options (CCO) text module

Stacey Stein, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: February 1, 2023 Expired: January 31, 2024

Read expert advice about the importance of managing adjuvant abemaciclib adverse events in early breast cancer, from Clinical Care Options (CCO)

Julia LaBarbera, MSN, RN, AGACNP-BC Released: January 31, 2023

Mark Pegram, MD, and Sara Tolaney, MD, MPH, discuss treatment and optimal management approaches for patients with TNBC, from Clinical Care Options (CCO)

Mark Pegram, MD Sara Tolaney, MD, MPH Released: January 31, 2023

Phase II trial evaluating pemigatinib for previously treated mCRC with FGF/FGFR alterations, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings